Compare BCSF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCSF | EVO |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.8M | 934.1M |
| IPO Year | 2015 | N/A |
| Metric | BCSF | EVO |
|---|---|---|
| Price | $13.11 | $3.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.00 | $7.00 |
| AVG Volume (30 Days) | ★ 428.9K | 107.4K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | ★ 14.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | $8.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.82 | $2.31 |
| 52 Week High | $16.00 | $4.80 |
| Indicator | BCSF | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 60.08 |
| Support Level | $11.92 | $2.87 |
| Resistance Level | $14.53 | $3.78 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 55.56 | 71.91 |
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.